STP-061002 is under clinical development by ST Pharm and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase I drugs for Kidney Cancer (Renal Cell Cancer) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STP-061002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STP-061002 overview

STP-061002 is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, gastric cancer, renal cell cancer and hepatocellular carcinoma. The drug candidate is administered through oral route in the form of capsule. It acts by targeting tankyrase (TNKS).

ST Pharm overview

ST Pharm provides custom manufacturing services for active pharmaceutical ingredient (API) and their intermediates. It provides nucleoside-based active pharmaceuticals in various antiviral drug applications. ST Pharm develops products for asthma, anti-fungal, anti-coagulant, anti-hyperlipidemia, anti-cancer, anti-tuberculosis, chronic obstructive pulmonary disease (COPD), cough suppressant, and anti-hypertensive. The company also develops drugs for MRI contrast agents, epilepsy, hepatitis B, diabetes mellitus, and erectile dysfunction medicine. The company is a subsidiary of Dong-A Socio Holdings Co Ltd. ST Pharm headquartered in Siheung, Seoul, South Korea.

For a complete picture of STP-061002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.